The stable pyrimidines UDPβS and UTPγS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery

[1]  D. Erlinge,et al.  Endothelial P2Y receptors induce hyperpolarisation of vascular smooth muscle by release of endothelium-derived hyperpolarising factor. , 1999, European journal of pharmacology.

[2]  T. K. Harden,et al.  Agonist action of adenosine triphosphates at the human P2Y1 receptor. , 1998, Molecular pharmacology.

[3]  S. Hartley,et al.  Functional evidence for a novel suramin-insensitive pyrimidine receptor in rat small pulmonary arteries. , 1998, Circulation research.

[4]  E. Barnard,et al.  Molecular Cloning and Characterization of the Rat P2Y4 Receptor , 1998, Journal of neurochemistry.

[5]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.

[6]  K. Starke,et al.  Is adenosine 3-phosphate 5-phosphosulfate a selective P2Y-receptor antagonist in intact tissues? , 1998 .

[7]  K. Starke,et al.  On the suitability of adenosine 3'-phosphate 5'-phosphosulphate as a selective P2Y receptor antagonist in intact tissues. , 1998, European journal of pharmacology.

[8]  K. Burke,et al.  Evidence that ATP acts at two sites to evoke contraction in the rat isolated tail artery , 1998, British journal of pharmacology.

[9]  X. Weng,et al.  [Extracellular ATP: effects, sources and fate]. , 1998, Sheng li ke xue jin zhan [Progress in physiology].

[10]  D. Erlinge,et al.  P2U‐receptor mediated endothelium‐dependent but nitric oxide‐independent vascular relaxation , 1998, British journal of pharmacology.

[11]  K. Jacobson,et al.  Structure Activity Relationships of P2 Receptor Agonists and Antagonists , 1998 .

[12]  T. K. Harden,et al.  Pharmacological Selectivities of Molecularly Defined Subtypes of P2Y Receptors , 1998 .

[13]  S. Chiba,et al.  UTP induces vascular responses in the isolated and perfused canine epicardial coronary artery via UTP‐preferring P2Y receptors , 1997, British journal of pharmacology.

[14]  R. Boucher,et al.  Identification of an Ecto-nucleoside Diphosphokinase and Its Contribution to Interconversion of P2 Receptor Agonists* , 1997, The Journal of Biological Chemistry.

[15]  J. Cazenave,et al.  The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells , 1997, FEBS letters.

[16]  S. Hartley,et al.  Electrophysiological consequences of purinergic receptor stimulation in isolated rat pulmonary arterial myocytes. , 1997, Circulation research.

[17]  T. K. Harden,et al.  Identification of competitive antagonists of the P2Y1 receptor. , 1996, Molecular pharmacology.

[18]  W. Watt,et al.  Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. , 1996, Molecular Pharmacology.

[19]  R Elde,et al.  Differential distribution of two ATP-gated channels (P2X receptors) determined by immunocytochemistry. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Burnstock,et al.  Discrimination by PPADS between endothelial P2Y‐ and P2U‐ purinoceptors in the rat isolated mesenteric arterial bed , 1996, British journal of pharmacology.

[21]  R. Andriantsitohaina,et al.  Calcium handling and purinoceptor subtypes involved in ATP‐induced contraction in rat small mesenteric arteries. , 1996, The Journal of physiology.

[22]  J. Schrader,et al.  Cloning of the rat P2u receptor and its potential role in coronary vasodilation. , 1996, The American journal of physiology.

[23]  W. Watt,et al.  Enzymatic synthesis of UTPγS, a potent hydrolysis resistant agonist of P2U‐purinoceptors , 1996 .

[24]  G. M. Smith,et al.  Cloning and Characterization of a Bovine P2Y Receptor , 1995 .

[25]  R. Evans,et al.  Characterization of P2‐purinoceptors in the smooth muscle of the rat tail artery: a comparison between contractile and electrophysiological responses , 1994, British journal of pharmacology.

[26]  R. North,et al.  A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP , 1994, Nature.

[27]  G. Burnstock,et al.  Analysis of P2-Purinoceptor Subtypes on the Smooth Muscle and Endothelium of Rabbit Coronary Artery , 1994, Journal of cardiovascular pharmacology.

[28]  G. Wilkinson,et al.  P2Y purinoceptor and nucleotide receptor-induced relaxation of precontracted bovine aortic collateral artery rings: differential sensitivity to suramin and indomethacin. , 1994, The Journal of pharmacology and experimental therapeutics.

[29]  S. Pirotton,et al.  Heterogeneity of ATP receptors in aortic endothelial cells. Involvement of P2y and P2u receptors in inositol phosphate response. , 1993, Circulation research.

[30]  G. Burnstock,et al.  Effects of purines and pyrimidines on the rat mesenteric arterial bed. , 1991, Circulation research.

[31]  P. Sever,et al.  The effects of adenosine triphosphate (ATP) and related purines on human isolated subcutaneous and omental resistance arteries , 1991, British journal of pharmacology.

[32]  G. Burnstock,et al.  Vascular control by purines with emphasis on the coronary system. , 1989, European heart journal.

[33]  G. Burnstock,et al.  Different P2-purinergic receptor subtypes of endothelium and smooth muscle in canine blood vessels. , 1987, The Journal of pharmacology and experimental therapeutics.

[34]  J. L. Gordon.  Extracellular ATP: effects, sources and fate. , 1986, The Biochemical journal.

[35]  G. Burnstock,et al.  The use of the slowly degradable analog, alpha, beta-methylene ATP, to produce desensitisation of the P2-purinoceptor: effect on non-adrenergic, non-cholinergic responses of the guinea-pig urinary bladder. , 1982, European journal of pharmacology.

[36]  R. Schirmer,et al.  The enzymatic synthesis of thiophosphate analogs of nucleotides. , 1972, Biochimica et biophysica acta.

[37]  M. da Prada,et al.  Adenine-, guanine- and uridine-5'-phosphonucleotides in blood platelets and storage organelles of various species. , 1971, The Journal of pharmacology and experimental therapeutics.